COVID-19 Therapeutic Alert

The UK-wide clinical commissioning policy has now been revised to reflect the availability of the nMAB sotrovimab (from the week commencing 20 December) and the current understanding of the likely impact of the Omicron variant on the efficacy of the combination nMAB casirivimab and imdevimab.

Further information on the updated policy and actions can be found in the alert.